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Introduction: Medication errors are the most frequent
cause of preventable harm in hospitals. Medication
management in paediatric patients is particularly
complex and consequently potential for harms are
greater than in adults. Electronic medication
management (eMM) systems are heralded as a highly
effective intervention to reduce adverse drug events
(ADEs), yet internationally evidence of their
effectiveness in paediatric populations is limited. This
study will assess the effectiveness of an eMM system
to reduce medication errors, ADEs and length of stay
(LOS). The study will also investigate system impact on
clinical work processes.
Methods and analysis: A stepped-wedge cluster
randomised controlled trial (SWCRCT) will measure
changes pre-eMM and post-eMM system
implementation in prescribing and medication
administration error (MAE) rates, potential and actual
ADEs, and average LOS. In stage 1, 8 wards within the
first paediatric hospital will be randomised to receive the
eMM system 1 week apart. In stage 2, the second
paediatric hospital will randomise implementation of a
modified eMM and outcomes will be assessed.
Prescribing errors will be identified through record
reviews, and MAEs through direct observation of nurses
and record reviews. Actual and potential severity will be
assigned. Outcomes will be assessed at the patient-level
using mixed models, taking into account correlation of
admissions within wards and multiple admissions for
the same patient, with adjustment for potential
confounders. Interviews and direct observation of
clinicians will investigate the effects of the system on
workflow. Data from site 1 will be used to develop
improvements in the eMM and implemented at site 2,
where the SWCRCT design will be repeated (stage 2).
Ethics and dissemination: The research has been
approved by the Human Research Ethics Committee of
the Sydney Children’s Hospitals Network and Macquarie
University. Results will be reported through academic
journals and seminar and conference presentations.
Trial registration number: Australian New Zealand
Clinical Trials Registry (ANZCTR) 370325.
Strengths and limitations of this study
▪ The stepped-wedge cluster randomised con-
trolled trial (SWCRCT) study design is the closest
to the gold standard of a randomised controlled
trial, and has rarely been applied to study the
effects of information technology in healthcare.
▪ Few previous studies have investigated the impact
of electronic systems on medication administra-
tion error rates. We present a novel approach to
conduct direct observation of this process using
the Precise Observation System for Safe Use of
Medicines (POSSUM). POSSUM allows observers
to quickly and accurately record drug information,
for example, name, strength, compliance with
procedures, as well as the number and length of
interruptions and multitasking.
▪ We will assess potential harm from medication
errors identified and importantly also measure
actual harm to children.
▪ Direct, close observation lends itself to the
‘Hawthorne effect’ whereby participants may
seek to ‘improve’ their performance. This may
result in an underestimation of the ‘true’ medica-
tion administration error rate.
▪ This study will not evaluate adverse drug events
occurring postdischarge.
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INTRODUCTION
Prescribing, administering and monitoring medicines in
children is highly complex. Compared with adults, medi-
cation errors in children are three times more likely to
result in harm.1 Paediatric patients are at particular risk
of certain errors, such as 10-fold dosing errors facilitated
by mistakes in dose calculation, poor documentation of
decimal points and confusion with the use of zeros.
Some errors have led to death.2–4 The complex medica-
tion decision process in children often requires informa-
tion about age, weight, dosing ranges and off-label use
of medicines.2 Systematic reviews show errors occur in
5–27% of all medication orders for children.5–7
Prescribing errors account for 3–37% of errors, dispens-
ing 5–58%, administration 72–75% and documentation
17–21%, although accuracy of estimates is affected by
the great variability in deﬁnitions and measurement
methods used.6 There is much less research about the
harms associated with medicine use. One Australian
study found 19.2% of paediatric inpatients experienced
adverse drug events (ADEs) and estimated 12.3% were
potential ADEs, 7.0% were actual ADEs and 3.6% were
preventable.8
The frequency and severity of medication administra-
tion errors (MAEs) in Australian adult hospitals is a
cause for concern.9 10 In 4271 medications administered
to 720 patients, 74.4% were found to have at least one
procedural failure (eg, failure to check a patient’s identi-
ﬁcation).9 10 One in four had a clinical error (eg, wrong
dose). Of intravenous drug administrations, 70% had
one clinical error, of which 25.5% were judged to be
serious and likely to cause permanent harm.9 MAEs
among children are rarely studied.6 11 A major barrier
to MAE research is the methodological challenges.
MAEs cannot be accurately detected from retrospective
record reviews; they require direct observation of nurses
administering medications to patients.
Can information technology reduce medication errors?
Electronic medication management (eMM) systems
incorporate software which provides users with the
ability to prescribe, monitor and administer medications
to patients. These systems also provide the capacity to
incorporate decision support tools such as alerts for
drug–drug interactions.12 eMM is usually integrated into
a hospital’s clinical information system (computerised
provider order entry system). These systems are expected
to reduce medication errors and ADEs signiﬁcantly as a
result of improved legibility of medication orders, com-
plete and legally compliant documentation, and
through both the active and passive decision support
tools embedded in them. However, rigorous evidence
demonstrating these effects is limited.7 A systematic
review identiﬁed eight studies of eMM effectiveness
among paediatric patients. Meta-analysis showed a sig-
niﬁcant reduction in prescribing error risk (RR 0.08;
95% CI 0.01 to 0.77) across the three included studies,
but not in ADEs or mortality.13 There are no Australian
studies of eMM system use in a paediatric setting.
Previous studies have often relied on incident reports to
measure error rates, which are generally unreliable.14
Only one study15 of paediatric inpatients has used a
control group to assess eMM effectiveness.
Internationally there is currently insufﬁcient evidence to
demonstrate clinical beneﬁt from eMM in paediatric
patients. This view was conﬁrmed by a policy review for
the American Academy of Pediatrics16 which called for
the demonstrable enhancement of eMM systems to
better meet the speciﬁc needs of paediatrics to ensure
their safety and effectiveness. Further, existing eMM
systems used in paediatrics have been found lacking in
functionalities required for safe prescribing, dispensing
and administration of medications.17 18
In 2005, Han et al19 reported a signiﬁcant increase in
the mortality rate among critical care children at a US
paediatric hospital following introduction of a commer-
cial eMM system. The rapid implementation process and
limited attention to the signiﬁcant workﬂow redesign
required were considered as major factors in this
outcome. Subsequent studies20 have shown no increase
in mortality rates. However, the Han et al19 study caused
considerable alarm and served to demonstrate the sub-
stantial dangers of poor implementation and the impor-
tance of monitoring outcomes following system
implementation and responding to the problems
identiﬁed.21
eMM use in adult hospitals, while highly effective at
reducing medication errors,22 also introduced new
‘system-related’ errors. An investigation of 1164 prescrib-
ing errors post-eMM in two adult Australian hospitals
found 42.4% were facilitated by the system (78 per 100
admissions).23 The most frequent mechanism was incor-
rect selection from a drop-down menu. Results from that
study were used to instigate changes to eMM software
and to inform changes to user training programmes.
The study was one of the ﬁrst to quantify the rate of
‘system-related’ errors and produced an innovative dual
classiﬁcation for categorising both the manifestations
and mechanisms of these system-related errors.23 The
nature and magnitude of such potential new risks have
rarely been studied in paediatrics.
Why evaluate eHealth systems
eHealth systems are having an increasing impact on the
delivery of healthcare services, yet, despite their wide-
spread effects and vast cost, they are rarely subject to
rigorous research.24 This limited evidence base signiﬁ-
cantly hinders improvements and innovation in the
design, implementation and use of health information
technology (IT) systems. Internationally the need for IT
evaluation studies to employ more robust designs and
sophisticated analyses is well recognised.25 Excessive reli-
ance has been placed on uncontrolled before-and-after
and qualitative studies. Evidence of eHealth system
effectiveness and safety is crucial to facilitate policy-
makers’ and healthcare organisations’ informed
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decisions about investments and prioritisation of health
IT systems.
This project presents an innovative and comprehen-
sive programme to assess eMM system’s effectiveness in
reducing medication errors, ADEs and length of stay
(LOS) and rapidly deploying new knowledge into prac-
tice for subsequent implementation.
The project aims are:
Aim 1: to quantify the safety and effectiveness of an
eMM system to reduce medication errors, ADEs and
average LOS among paediatric patients using a
stepped-wedge cluster randomised controlled trial
(SWCRCT) design;
Aim 2: to assess the effects of the eMM on clinicians’
workﬂow and efﬁciency; and
Aim 3: to assess the extent to which feedback of study
results and subsequent modiﬁcations to the eMM
design and associated work practices can improve eMM
effectiveness in reducing medication errors at a subse-




Quantify the safety and effectiveness of an eMM system
to reduce medication errors (potential and actual
ADEs), and average LOS among paediatric patients.
Study design and setting
We will conduct a SWCRCT to measure changes in pre-
scribing and MAEs which result in potential and actual
ADEs, along with changes in average LOS, pre-eMM and
post-eMM. Cluster randomised controlled trials (CRCT)
are ideally suited to test interventions where individual
patient randomisation is not possible. CRCTs commonly
use a parallel group design, in which the clusters are
randomised to either the intervention or the control
arm of the study. It is often regarded as unethical to
withhold an intervention from a proportion of partici-
pants if it is believed that the intervention will do more
good than harm. The SWCRCT design, where the inter-
vention is delivered sequentially to all trial clusters over
a number of time periods, is an alternative to the trad-
itional parallel groups design. The order in which the
clusters (wards) receive the intervention is randomised,
and by the end of the study all clusters will have adopted
the intervention.26 The steps represent the predeter-
mined periods when data relating to each of the clusters
will be collected. This design is the closest to the gold
standard of an RCT, when such a design is not possible.
The stepped-wedge design offers particular strengths in
allowing the modelling of the effect of time on the
effectiveness of the intervention. In stage 1 a SWCRCT
will be conducted at site 1, and in stage 2 a SWCRCT
will be conducted at site 2.
The study setting is the Sydney Children’s Hospitals
Network which incorporates the two major urban
tertiary referral paediatric hospitals in Sydney, Australia,
The Children’s Hospital at Westmead (CHW; site 1) and
Sydney Children’s Hospital, Randwick (SCH; site 2).
The network provides care for 51 000 inpatient admis-
sions, 92 000 emergency department presentations and
over 1 000 000 outpatient services events each year. Both
sites are acute paediatric tertiary hospitals with emer-
gency departments, outpatient and home services.
During the study period, the eMM will not be available
in the intensive care units (ICUs), theatres or outpati-
ents. Site 1 accommodates 310 beds and site 2 has 180
beds. Both hospitals provide a complex and comprehen-
sive range of services caring for seriously ill and injured
children and adolescents across the state of New South
Wales and beyond.
The eMM intervention
At baseline medication orders are written on paper
medication charts and details of medications adminis-
tered are written on the same charts. The eMM clinical
module will be an addition to the hospitals’ existing
commercial electronic clinical information system
(Cerner Corporation). Both hospital sites use the same
commercial clinical system; however, the software can be
customised to meet each hospital’s individual require-
ments. Based on the results from our ﬁrst site and
applying our action research methodology, we will
provide advice to the second implementation site on
optimal customisation of the eMM (and associated pro-
cesses) for their site. The eMM allows electronic pre-
scribing, recording of drug dispensing, drug
administration and medication reconciliation and moni-
toring processes (see online supplementary material ﬁle
for screenshots from the eMM). The system allows for
the ordering and administration of all oral, and intrve-
nous medications and ﬂuids, but excludes anaesthesia
medications. The eMM contains both passive and active
decision support in the form of links to guidelines, pol-
icies, protocols, order sets, order sentences, safety alerts
(eg, drug–drug interactions, dose range checks) and
dosage calculators. During the course of the study, the
eMM system will be accessible via any computer in the
hospital allocated for inpatient clinical care, but will not
be available for patients in the ICUs, theatres or outpati-
ents. The system will be predominantly accessed in hos-
pital wards and in the hospital pharmacy. Both ﬁxed
and mobile computing devices are available to staff
using the system.
Medication reconciliation on admission and at dis-
charge will be performed using the eMM system when
implemented. On admission, medication histories are
taken and converted to inpatient orders. While the
patient is in hospital any new medication orders will be
created within the eMM system. On discharge, a dis-
charge medication reconciliation occurs and orders are
converted to paper prescriptions for the patient.
Patients then have their prescriptions ﬁlled at commu-
nity pharmacies.
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Randomisation
In stage 1, eight wards within site 1 will be randomised
to receive the eMM system. Randomisation will be con-
ducted by a person blinded to ward identity. At baseline,
all eight wards are in the control period (ﬁgure 1). At
step 1, the eMM system will be implemented in the ﬁrst
ward. The eMM system will then be implemented to a
new ward in sequence weekly. By the end of step 8, all
wards will have the eMM system at site 1.
Medication error and ADE definitions
Medication errors are deﬁned as any error in the pre-
scribing, supply, preparation, administration or monitor-
ing of a medication, regardless of whether such errors
lead to adverse consequences. In this study, we will not
measure dispensing errors. ADEs are deﬁned as harm or
injury as a consequence of the use or non-use of medi-
cines.8 Medication errors may result in actual ADEs or
potential ADEs. For example, a medication error may
occur but is intercepted prior to administration thus pre-
venting harm to the patient.
In this study, we will be seeking to identify medication
errors, and to determine those that resulted in harm
(actual ADEs) or potential harm (potential ADEs).
Figure 2 illustrates the medication error and ADE classi-
ﬁcation processes for this study.
Data collection
Medication error data collection occurs at baseline
(1 week period) and each step (ie, in every subsequent
week as eMM implementation occurs and for 2 add-
itional weeks after full implementation). For the primary
study objective of determining eMM effectiveness to
reduce medication errors and ADEs, we will collect data
at 11 points on all wards (baseline and at each step
including 2 weeks after full implementation, ﬁgure 1).
This will allow us to measure changes pre-eMM and
post-eMM system introduction in: (1) prescribing error
rates per order and per admission by type and severity
(potential and actual ADEs); (2) MAEs per order and
per admission by type and severity (potential and actual
ADEs). For the secondary outcome of changes in LOS,
we will obtain data for a further 21 steps in the follow-up
period to provide greater statistical power. As these are
routine administrative data, no additional data collection
is required. Data on ADEs occurring postdischarge is
not within the scope of this study.
Prescribing error and ADE detection: A review of medica-
tion charts at baseline and each step will be conducted
complying with a standard error protocol.8–10 22 This
protocol will be extended to develop methods for deter-
mining the rate at which errors are detected and inter-
cepted by staff, actions taken and any harm
experienced.
MAE and ADE detection: For the MAE study, data will be
collected using direct observation. Nurses will be
observed preparing and administering medications. In
our previous studies using this approach in adult hospi-
tals,10 over 80% of nurses consented to participate and
we expect similar rates for this study. Direct observations
will be supported by an innovative data collection tool,
the Precise Observation System for Safe Use of
Medicines (POSSUM, ﬁgure 3).10 27 The POSSUM tool
allows observers to quickly and accurately record drug
information, for example, name, strength and dose. The
POSSUM tool also allows collection of the number and
length of interruptions experienced and multitasking
(eg, answering a question while also selecting medi-
cines). Nurses’ compliance with core procedures, such
as checking a patient’s identiﬁcation, will also be
recorded. Comparing observational data with patients’
medical records (via retrospective audit) will enable
identiﬁcation of the number, types and severity of MAEs.
Observers will have a preallocated observation period
to ensure coverage across the day and the week.9 10
Observers will follow a ‘serious error’ protocol, that is,
they must intervene if they witness an administration
that is potentially dangerous to the patient. Observers
will not have access to patients’ medication charts and
will record only what they observe. Thus, most MAEs will
not be identiﬁable until chart review. Past inter-rater reli-
ability tests showed κ scores from 0.94 to 0.96 following
training in the use of POSSUM.9 10
Direct, close observation lends itself to the
‘Hawthorne effect’ whereby participants may seek to
‘improve’ their performance. If nurses change their
practices, and are more careful when observed, this will
lead to an underestimation of the ‘true’ MAE rate. This
bias would be present both pre-eMM and post-eMM.
Our prior research suggests the likelihood of sustained
change on busy wards is low.28 29
Prescribing error, MAE and ADE classiﬁcations:
Prescribing errors and MAEs will be classiﬁed into: (1)
procedural errors and (2) clinical errors using previously
Figure 1 Schematic of stepped-wedge cluster randomised controlled trial study design.
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applied classiﬁcations.10 22 Procedural errors include,
for prescribing orders, illegible orders, illegal orders (in
which an aspect of the prescription does not comply
with hospital policy, with law, or with the State
Department of Health policies) and incomplete orders.
Medication administration procedural errors include,
for example, failure to follow the correct patient identiﬁ-
cation process prior to drug administration, and correct
conduct of medication double-checking requirements
(many drugs within paediatric hospitals require two
nurses to independently check aspects of the drug prep-
aration and administration process). Clinical errors
include wrong dose, wrong drug, wrong route and
wrong strength errors.
Once an error has been identiﬁed, a rating of the
potential severity of that error will be made, based on
the National Coordinating Council for Medication Error
Reporting and Prevention (NCC-MERP) rating scale for
adverse event outcomes.30 Subsequently, records will be
reviewed for the evidence of error detection and inter-
ception, and for any actual harm to the patient. Thus,
medication errors which occur will receive both a
‘potential’ harm rating and an ‘actual harm rating’
(ﬁgure 2). As most previous medication error studies do
not assess actual harm, this double classiﬁcation process
will allow us to compare our ﬁndings with previous
studies, as well as allow an assessment of the accuracy of
such approaches compared with estimating the actual
harm from medication errors.
Evidence of harm as a consequence of a medication
error will be identiﬁed through a comprehensive review
of patients’ medical records. This clinical review process
will be assisted by the provision of speciﬁc harm identiﬁ-
cation guides for reviewers which will identify, for
speciﬁc drugs and error types, the types of evidence
which would suggest harm had occurred following the
medication error. Figure 4 presents an example of one
of the harm identiﬁcation guides to be used.
Experienced clinicians will abstract data from medical
records using a structured data collection form and the
harm identiﬁcation guides. A multidisciplinary clinical
review panel will reassess a minimum 5% sample of the
records and will also review any records which reviewers
identify as particularly complex. Panel members will be
blind to the location, and whether data were generated
pre-eMM or post-eMM. Panel members will not know the
ward order of rollout and speciﬁc dates when each ward
became an intervention ward with the stepped-wedge
design and therefore blinding of predata and postdata
will be possible. Actual and potential severity will be
assigned using the NCC-MERP scale for adverse event
outcomes30 and the 5-point Severity Assessment Code (SAC)
Scale,31 as used in our past research.9 10 22 This will allow
comparison with a greater number of previous studies.
System-related errors: We will apply our two-dimensional
classiﬁcation, modiﬁed to incorporate recent recommen-
dations in this area,21 to assess whether medication
errors post-eMM were facilitated by eMM design, that is,
are ‘system-related’. This process identiﬁes the manifest-
ation (eg, wrong dose) and mechanisms (eg, incorrect
menu selection). These results will be used to provide
recommendations about IT design and user training.23
Any changes to the eMM design features, training or
work processes during the study will be documented.
Sample sizes and analyses
Sample size calculations have taken into account the esti-
mated between-cluster variance, that is, between wards
Figure 2 Medication error, ADE and harm identification and classification process. ADE, adverse drug event.
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variance, and the design effect associated with the
stepped-wedge design.32 Calculations were based on our
previous studies in adult hospitals and hospital data
from the paediatric sites. Each ward has on average 14
admissions per week with an average LOS 3.78 days
(SD=7.39) with seven medications per admission.
Prescribing errors: Based on our previous studies22 the
expected reduction in overall prescribing error rate is
60%, from 4.06 errors per admission (SD=5.27) to 1.62
(SD=2.87) with an estimated intraclass correlation coefﬁ-
cient (ICC) of 0.06 (table 1). The number of wards
required to detect a 60% change for two-sided tests
(80% power; α<5%) is one, with 10 data collection steps
after baseline. For ADEs, the required number of wards
is seven to detect a 60% reduction (table 1). To be con-
servative and provide greater power, we will collect data
on all eight wards allowing detection of a minimum
change of 20% for overall errors and 42% for ADEs. At
each step records for 112 patient admissions will be
reviewed, totalling 1232 across the study.
MAEs: Based on our previous studies9 10 we expect the
overall MAE rate per administration to fall by 27%, from
Figure 3 POSSUM tool for data
collection during the direct
observational study of medication
administration. POSSUM, Precise
Observation System for Safe Use
of Medicines.
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0.37 (SD=0.65) to 0.27 (SD=0.52) with an estimated ICC
of 0.03 (table 1). The required number of wards (two-
sided test; 80% power; α<5%) is seven, with 10 steps
after baseline. For ADEs, the required number of wards
is six. We will collect data using all eight wards which will
allow detection of a minimum 20% change overall and
48% for ADEs. At each step we will observe at least 240
medication administrations, totalling 2640 across the
study.
LOS: There are very limited data on the impact of
eMM systems on LOS at ward level. A study in an ICU
showed a 23% reduction in LOS post-eMM system.33 To
detect a 23% reduction in LOS, that is, from 3.78
(SD=7.39) to 2.92 days, with eight wards, will require
(routinely collected LOS) data in a total of 31 steps for a
two-sided test with 80% power α<5%.
Data analyses
Medication error rates per order, stratiﬁed by error type,
study step and ward will be calculated. For each outcome
of interest, data collected across all measurement
periods and all study steps will be used in the analyses
comparing intervention status (pre-eMM vs post-eMM).
Analyses will apply the intention-to-treat principle.
Patient data will be analysed according to the status of
the wards (ie, pre-eMM or post-eMM) where patients
were admitted. Outcomes will be assessed at the patient
level using mixed models, taking into account correl-
ation of patient admissions within wards (clusters) and
multiple admissions for the same patient, with adjust-
ment for potential confounding factors. For the MAE
analyses, we will adjust for contextual factors including
interruptions, multitasking, nurse age, gender and
adherence to policies. For LOS analysis we will adjust for
patient characteristics, such as major diagnoses,
comorbidity, age and gender. The mixed models will
incorporate ﬁxed terms for ward intervention status,
measurement time steps (including baseline) and other
confounders. The analyses will include multiple time
points pre-eMM and post-eMM implementation. The
study design will allow us to determine temporal changes
in system effectiveness, for example, to determine if
error rates continue to decline over time. We will apply
the ‘system-related’ error classiﬁcation23 to identify
system-related error rate and associated mechanisms.
Aim 2
To assess the effects of the eMM on workﬂow and
efﬁciency.
Study design and sample
Observations and interviews will be held with medical,
nursing and pharmacy staff at baseline to allow mapping
of core work processes associated with medication provi-
sion. At each step in the stepped-wedge design, a small
number of interviews (∼4 on each ward) will be con-
ducted with nursing and medical staff to gain insights
into clinical staff perceptions of the impact of the system
on workﬂow, efﬁciency and care delivery. These inter-
views will be held 1, 3, 6 weeks and 6 months post-eMM
implementation on each study ward. Members of the
research team will directly approach hospital staff and
Figure 4 Example of harm
assessment guide for paediatric
opioid errors, to be used during
medical record review following
identification of an opioid
prescribing error. BP, blood
pressure; ICU, intensive care unit.
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invite them to participate in interviews which will take
∼10 min each. We anticipate ∼80–90 interviews will be
conducted across the course of the study.
Trustworthiness of the qualitative data will be achieved
through triangulation of data and investigators, engage-
ment with the ﬁeld with a documented audit trail and
member checking.34
The eMM is anticipated to have a signiﬁcant impact
on the work of hospital pharmacists. We will conduct a
direct observational study of ∼8 pharmacists at site 1. We
will observe them for 200 hours between 7:30 and 18:00
pre-eMM and post-eMM system implementation to
examine changes in (1) task time distributions, (2) loca-
tion of work and (3) communication patterns. Using the
validated the Work Observation Method By Activity
Timing (WOMBAT) approach35 36 multiple dimensions
of work will be captured (eg, tasks performed, with
whom, with what, location, interruptions and multitask-
ing). On data entry, tasks are automatically time
stamped when entered in the WOMBAT data collection
tool. Figure 5 is an example of data collection within
WOMBAT. An additional sample of 140 hours of obser-
vation will be conducted to capture the work of oncol-
ogy pharmacists whose work involves supporting the
delivery of complex drug regimens to children with
cancer.
Data generated will allow changes in task time distribu-
tions and sequencing of work to be determined. These
data will be examined in relation to changes in outcome
indicators generated (from aim 1, eg, medication error
rates, LOS) on the same wards.
Aim 3
Assess the extent to which feedback (from aims 1 and 2)
and subsequent modiﬁcations to an eMM system design
can improve eMM system effectiveness in reducing medi-
cation errors.
Evaluations of health IT serve multiple purposes,
ranging from providing an objective assessment of the
success of the new technology in delivering anticipated
beneﬁts, to identiﬁcation of deﬁcits in the system, their
source and the ways they can be addressed. This is crit-
ical to improving system effectiveness, relevance and
responsiveness. For aim 3, the ﬁndings of the SWCRCT
at CHW (ie, stage 1) will be reported to the Project
Evaluation Committee (PEC) made up of members of
the research team, and the hospitals’ eMM system
Project Steering Committee. The PEC will meet every
month to consider the implications of study ﬁndings
across a number of domains including the system’s tech-
nical features (eg, compatibility with other hospital
systems), effectiveness (eg, error reduction and system-
related errors); professional attitudes (eg, satisfaction)
and organisational features (eg, work processes), as a
means of formulating changes to eMM system design
features and user training.
This will form the key component of an
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performance leading to an enhanced eMM system
which will then be implemented across the second site,
SCH (stage 2). The SWCRCT design will be repeated at
site 2 using the same methods as above. Power calcula-
tions for stage 2 will be based on results from stage
1. We will conduct separate analyses for all outcomes
speciﬁed. Results for the two sites will be compared,
using multilevel and longitudinal analysis approaches to
determine changes in error rates (taking baseline data
into account).
Expected outcomes and significance of the research
project
This project will generate the ﬁrst Australian data, in a
paediatric setting, on the effectiveness of eMM systems
to reduce medication errors and ADEs, and provide an
assessment of how systems impact on the work of clini-
cians and the consequences for the delivery of care to
children. Importantly, the ﬁndings will be directly
applied to enhance the eMM system design, and work
processes and then tested further through evaluation of
Figure 5 WOMBAT for
conducting observational studies
of health professionals’ work
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the enhanced eMM system at a second paediatric hos-
pital. These results will be particularly valuable for
other paediatric hospitals yet to start implementations.
Exploiting the SWCRCT design within an action
research model is highly innovative, and will deliver
high-quality data on system effectiveness. Such a model
of formally integrating health IT assessment results as a
basis for active engagement with IT vendors and clini-
cians to bring about system change has both national
and international signiﬁcance. The study advances expli-
cit methods for the systematic identiﬁcation of harm
associated with medication errors. The data generated
will also provide the basis for a robust cost-effectiveness
analysis, which will be the subject of a separate
protocol.
ETHICS AND DISSEMINATION
The research has been approved by the Human
Research Ethics Committee of the Sydney Children’s
Hospitals Network (HREC/15/SCHN/370). In the ﬁrst
instance, results from site 1 will be reported to the PEC
so that they can be used to inform eMM system and work
process design prior to implementation at site 2. Results
will also be reported through academic journals and con-
ference presentations. The project is funded through a
National Health and Medical Research Council
Partnership Grant. As such, the project team includes
academic researchers, hospital clinicians and experts
involved in the implementation of the eMM system at
the two hospital sites, along with senior policymakers
from agencies within the State Health Department
involved in eHealth system strategy and policy. This pro-
vides the project with access to a range of other conduits
through which to disseminate results to, for example,
policymakers and system implementers.
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